Product Name: Bcl9L Antibody
Species Reactivity: Human
Tested Applications: ELISA, ICC, IF, IHC-P, WB
Applications: Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL and immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: Predicted: 165 kDa Observed: 195 kDa
Immunogen: Bcl9L antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human Bcl9L.The immunogen is located within amino acids 20 – 70 of Bcl9L.
Host Species: Rabbit
Purification: Bcl9L Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 32791-84-7
Product: Panaxatriol
Buffer: Bcl9L Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: Bcl9L antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Bcl9L Antibody: BCL9-2, DLNB11, Protein BCL9-2, B-cell lymphoma 9-like protein
Accession NO.: NP_872363
Protein Ino: 32698936
Official Symbol: BCL9L
Geneid: 283149
Background: Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.
PubMed ID:http://aac.asm.org/content/53/12/5060.abstract
